StockpollyBeta
Get App
Popularity #4,850
KYNB · NASDAQ · Biotechnology

Kyntra Bio (KYNB)

Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.

$7.24
vs last close−0.04 (−0.55%)

Something off on this page? Send us feedback.

13F · 13D/G · Form 4

Insiders2.20%89.2K shares
5 holders · as of Sep 9, 2026
Strategic holders9.88%400.0K shares
1 holder · as of May 15, 2026
Other87.92%3.56M shares
remainder

4.05M company shares as of Sep 23, 2026 · holders as of their latest filing

13F · 13D/G · Form 4

HolderStakeSharesDate
Armistice Capital, LLCStrategic
9.88%400,000filed May 15, 2026
James A. SchoeneckInsiderdirector
0.98%39,666filed Jul 2, 2025
Thane WettigInsiderdirector, officer: CEO
0.66%26,796filed Sep 9, 2026
Christine ChungInsiderofficer: SVP, CHINA OPERATIONS
0.29%11,796filed Mar 7, 2025
Juan GrahamInsiderofficer: CHIEF FINANCIAL OFFICER
0.16%6,595filed Dec 9, 2024
David DeLuciaInsiderofficer: Chief Financial Officer
0.11%4,355filed Sep 9, 2026
Rory B. Riggs1Insiderdirector
0.39%15,830filed May 28, 2021
Enrique A. Conterno2Insiderdirector, officer: Chief Executive Officer
0.37%14,989filed Jul 10, 2023
Pat Cotroneo3Insiderofficer: Executive Advisor & Former CFO
0.27%10,981filed Sep 9, 2021
K. Peony Yu4Insiderofficer: Chief Medical Officer
0.19%7,692filed Dec 17, 2020
Jorma Routti5Insiderdirector
0.16%6,462filed Mar 27, 2019
Mark Eisner6Insiderofficer: EVP, Chief Medical Officer
0.16%6,397filed Sep 8, 2023
Elias Kouchakji7Insiderofficer: SVP, Clinical Dev, Drug Safety
0.15%5,894filed Mar 10, 2021
Roberto Pedro Rosenkranz8Insiderdirector
0.09%3,844filed Jun 11, 2020
Deyaa Adib9Insiderofficer: Chief Medical Officer
0.08%3,285filed Jun 13, 2024
Toshinari Tamura10Insiderdirector
0.06%2,256filed Jun 7, 2019
Thomas B. Neff11Insiderdirector, officer: Chief Executive Officer
0.04%1,770filed Aug 23, 2019
Thomas F. Jr Kearns12Insiderdirector
0.04%1,591filed Sep 17, 2021
Kalevi Kurkijarvi1Insiderdirector
0.04%1,512filed May 28, 2021
Jeffrey L. Edwards13Insiderdirector
0.03%1,359filed Jun 9, 2023
Maykin Ho13Insiderdirector
0.03%1,260filed Jun 9, 2023
Suzanne Blaug13Insiderdirector
0.03%1,184filed Jun 9, 2023
Jeffrey William Henderson14Insiderdirector
0.03%1,155filed Sep 6, 2023
Gerald Lema13Insiderdirector
0.03%1,151filed Jun 9, 2023
Benjamin Cravatt13Insiderdirector
0.03%1,149filed Jun 9, 2023
  1. Last filed May 28, 2021; leaving the company requires no filing. Not in the bar.
  2. Last filed Jul 10, 2023; leaving the company requires no filing. Not in the bar.
  3. Last filed Sep 9, 2021; leaving the company requires no filing. Not in the bar.
  4. Last filed Dec 17, 2020; leaving the company requires no filing. Not in the bar.
  5. Last filed Mar 27, 2019; leaving the company requires no filing. Not in the bar.
  6. Last filed Sep 8, 2023; leaving the company requires no filing. Not in the bar.
  7. Last filed Mar 10, 2021; leaving the company requires no filing. Not in the bar.
  8. Last filed Jun 11, 2020; leaving the company requires no filing. Not in the bar.
  9. Last filed Jun 13, 2024; leaving the company requires no filing. Not in the bar.
  10. Last filed Jun 7, 2019; leaving the company requires no filing. Not in the bar.
  11. Last filed Aug 23, 2019; leaving the company requires no filing. Not in the bar.
  12. Last filed Sep 17, 2021; leaving the company requires no filing. Not in the bar.
  13. Last filed Jun 9, 2023; leaving the company requires no filing. Not in the bar.
  14. Last filed Sep 6, 2023; leaving the company requires no filing. Not in the bar.

13F

No 13F holders on record.

13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Armistice Capital, LLC9.88%400.0K13GMay 15, 2026

Form 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
May 14, 2026
Thane Wettigdirector, officer: CEO
Purchase · 2 lots5,600$7.0927,203
Nov 13, 2025
Thane Wettigdirector, officer: CEO
Purchase1,000$9.1822,239
Nov 17, 2025
Thane Wettigdirector, officer: CEO
Purchase2,700$9.1024,939

House and Senate disclosures

Not reported.